Rinvoq 15mg Prolonged-release tablet.
PDF Leaflet Revision Date: 02 October 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Moderate to severe active rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, giant cell arteritis, atopic dermatitis, ulcerative colitis, Crohnu2019s disease.
Dosage (summary)
15 mg once daily; 30 mg for high disease burden or inadequate response.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding.
Key Drug Interactions
- Strong CYP3A4 inhibitors
- Strong CYP3A4 inducers
Contraindications
- Hypersensitivity
- Active tuberculosis
- Severe hepatic impairment
Common side effects
- Upper respiratory tract infections
- Nausea
- Neutropenia
- Increased liver enzymes
Counselling Points
- Monitor for infections.
- Avoid live vaccines.
- Use effective contraception during treatment.
Serious warnings
- Serious infections
- Malignancy risk
- Gastrointestinal perforations
Important Disclaimer
The Rinvoq 15mg Prolonged-release tablet. professional information leaflet below is the property of AbbVie and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
